Aim To investigate association of mean platelet volume (MPV) and glycemic control markers, and whether MPV could be used as a predictor of deterioration of glucoregulation in Diabetes mellitus type 2 (DMT2) patients. Methods The cross-sectional study included 106 DMT2 patients, treated at the Primary Health Care Centre in Zenica, distributed into groups according to glycated haemoglobin (HbA1c) values: A (n=44, HbA1c ≤7.0%) and B (n=62, HbA1c>7.0%). Spearman’s correlation coefficients were calculated to evaluate the relationships between MPV and glycemic control markers. Binomial logistic regression analysis was performed to estimate the relationship between glycemic control, as dichotomous outcome, and MPV as the main predictor. Diagnostic value of MPV as a marker for poor glucoregulation was estimated by using ROC analysis. Results Mean platelet volume was significantly higher in the group B compared to the group A (p<0.0005). Significant positive correlations of MPV with fasting blood glucose and HbA1c were found in the total sample (rho=0.382, p<0.0005; rho=0.430, p<0.0005, respectively). Mean platelet volume was positively associated with the risk of inadequate glycemic control, with 2 times increased odds of inadequate glycemic control per femtoliter greater MPV (Exp (β) =2.195; 95% CI=1.468 - 3.282, p<0.0005). The area under ROC curve for MPV was 0.726 (95% CI: =0.628-0.823, p <0.0005). At the best cut-off value 9.55 fL, MPV showed sensitivity of 82% and specificity of 54.5%. Conclusion Mean platelet volume correlates with glycemic control markers in DMT2 patients. It could be used as a simple and cost-effective predictor of deterioration of glucoregulation.
Sherwin R, Jastreboff A. Year in diabetes 2012: the diabetes tsunami. J Clin Endocrinol Metab. 2012. p. 4293–301.
2.
Shaw J, Sicree R, Zimmet P. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010. p. 4–14.
3.
Diagnosis and classification of diabetes mellitus. Diabetes Care. American Diabetes Association; 2011. p. 62–9.
4.
Classification and diagnosis of diabetes. Diabetes Care. American Diabetes Association; 2015. p. 8–16.
5.
Ferreiro J, Gómez-Hospital J, Angiolillo D. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res. 2010. p. 251–9.
6.
Jindal S, Gupta S, Gupta R, Kakkar A, Singh H, Gupta K, et al. Platelet indices in diabetes mellitus: indicators of diabetic microvascular complications. Hematology. 2011. p. 86–9.
7.
Kubisz P, Stančiaková L, Staško J, Galajda P, Mokáň M. Endothelial and platelet markers in diabetes mellitus type 2. World J Diabetes. 2015. p. 423–31.
8.
Kaplan Z, Jackson S. The role of platelets in atherothrombosis. Hematology Am Soc Hematol Educ Program. 2011. p. 51–61.
9.
Schneider D. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009. p. 525–7.
10.
Kakouros N, Rade J, Kourliouros A, Resar J. Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol. 2011. p. 742719.
11.
Vinik A, Erbas T, Park T, Nolan R, Pittenger G. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001. p. 1476–85.
12.
Michelson A. Methods for the measurement of platelet function. Am J Cardiol. 2009. p. 20–6.
13.
Chu S, Becker R, Berger P, Bhatt D, Eikelboom J, Konkle B, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost. 2010. p. 148–56.
14.
Kiliçli-Camur N, Demirtunç R, Konuralp C, Eskiser A, Başaran Y. Could mean platelet volume be a predictive marker for acute myocardial infarction? Med Sci Monit. 2005. p. 387–92.
15.
Khandekar M, Khurana A, Deshmukh S, Kakrani A, Katdare A, Inamdar A. Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: an Indian scenario. J Clin Pathol. 2006. p. 146–9.
16.
Bath P, Algert C, Chapman N, Neal B. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke. 2004. p. 622–6.
17.
Braekkan S, Mathiesen E, Njølstad I, Wilsgaard T, Størmer J, Hansen J. Mean platelet volume is a risk factor for venous thromboembolism: the Tromsø Study. J Thromb Haemost. 2010. p. 157–62.
18.
Han J, Choi D, Choi S, Kim B, Ki Y, Chung J, et al. Stroke or coronary artery disease prediction from mean platelet volume in patients with type 2 diabetes mellitus. Platelets. 2013. p. 401–6.
19.
Papanas N, Symeonidis G, Maltezos E, Mavridis G, Karavageli E, Vosnakidis T, et al. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets. 2004. p. 475–8.
20.
Demirtas L, Degirmenci H, Akbas E, Ozcicek A, Timuroglu A, Gurel A, et al. Association of hematological indicies with diabetes, impaired glucose regulation and microvascular complications of diabetes. Int J Clin Exp Med. 2015. p. 11420–7.
21.
Skyler J, Bergenstal R, Bonow R, Buse J, Deedwania P, Gale E, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. American Heart Association; 2009. p. 351–7.
22.
Demirtunc R, Duman D, Basar M, Bilgi M, Teomete M, Garip T. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. J Diabetes Complications. 2009. p. 89–94.
23.
Lemkes B, Hermanides J, Devries J, Holleman F, Meijers J, Hoekstra J. Hyperglycemia: a prothrombotic factor? JThromb Haemost. 2010. p. 1663–9.
24.
Winocour P, Watala C, Kinlough-Rathbone R. Membrane fluidity is related to the extent of glycation of proteins, but not to alterations in the cholesterol to phospholipid molar ratio in isolated platelet membranes from diabetic and control subjects. Thromb Haemost. 1992. p. 567–71.
25.
Keating F, Sobel B, Schneider D. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes. Am J Cardiol. 2003. p. 1362–5.
26.
Guthikonda S, Alviar C, Vaduganathan M, Arikan M, Tellez A, Delao T, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol. 2008. p. 743–9.
27.
Sharpe P, Trinick T. Mean platelet volume in diabetes mellitus. Q J Med. 1993. p. 739–42.
28.
Kodiatte T, Manikyam U, Rao S, Jagadish T, Reddy M, Lingaiah H, et al. Mean platelet volume in Type 2 diabetes mellitus. J Lab Physicians. 2012. p. 5–9.
29.
Dindar S, Cinemre H, Sengul E, Annakkaya A. Mean platelet volume is associated with glycaemic control and retinopathy in patients with type 2 diabetes mellitus. West Indian Med J. 2013. p. 519–23.
30.
Zaccardi F, Rocca B, Pitocco D, Tanese L, Rizzi A, Ghirlanda G. Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta-analysis. Diabetes Metab Res Rev. 2015. p. 402–10.
31.
Shah B, Sha D, Xie D, Mohler E, Berger J. The relationship between diabetes, metabolic syndrome, and platelet activity as measured by mean platelet volume: the National Health and Nutrition Examination Survey. Diabetes Care. 1999. p. 1074–8.
32.
Ozder A, Eker H. Investigation of mean platelet volume in patients with type 2 diabetes mellitus and in subjects with impaired fasting glucose: a costeffective tool in primary health care? Int J Clin Exp Med. 2014. p. 2292–7.
33.
Coban E, Bostan F, Ozdogan M. The mean platelet volume in subjects with impaired fasting glucose. Platelets. 2006. p. 67–9.
34.
Osende J, Badimon J, Fuster V, Herson P, Rabito P, Vidhun R, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol. 2001. p. 1307–12.
35.
Jagroop I, Tsiara S, Mikhailidis D. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets. 2003. p. 335–6.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
